Taking into account all relevant factors, Medical Properties Trust, Inc. (NYSE:MPW) scores 100% Buy on the technical side. The share price is also flashing a Buy from the Barchart TrendSpotter trading system. Investors starting out on a short-term path of investing should know that short terms indicators for MPW averaged 100% Buy with an average daily trading volume over the past 20 days at 9488950 shares. Those using medium-term investment strategies, the shares have overall a 1% Buy signal while the 50-day average daily volume remained almost 5734638 shares. It’s also important to note that the stock, whose average daily volume over the 100 days as of this piece was shares, is signaling100% Buy for long term investors.
The stock is lingering around the initial support level of $20.67. After this, the following support is at the zone of $20.32. Up until the time the MPW stock hit levels beyond the current one, bulls should have no alarm. In terms of its momentum, the stock’s RSI hit 62.32 on the daily chart, and this may be a cause for concern. In case the price goes below $20.32 level on closing basis, there may be more profit booking with the stock growing weaker. Still, getting to the $21.23 level may cause a pull-back move approaching $21.44 mark.
Medical Properties Trust, Inc. (MPW) is most likely going to rise 3.47 percent in the coming 12 months, as per price target approximations compiled by finviz. Nevertheless, they have set the price target at a $25-month high price target. This represents a whopping 18.93 percent increase from the current trading of shares. The 52-week median price target given by the analysts is $22, which means a return possibility of 4.66 percent in comparison with the closing price of the stock of $21.02 on December 03. The lowest price set for the stock is $18.5 — just above -11.99 percent from MPW share price now.
Let’s take a glimpse at some insider activity at Medical Properties Trust, Inc. (NYSE:MPW) and observe the pattern. The earliest insider trade happened on 10/10/2019. Aldag Edward K JR parted with a total of 101.96 thousand shares of the firm at average share price of $19.78. The total amount for the sale was set at $2.02 million. On completing this exchange, the Chairman, President & CEO account balance was 2.06 million shares. The stock grew 3.94 percent from that insider sale. On 09/25/2019, HAMNER R STEVEN, Executive Vice President & CFO, did a sale of 77.5 thousand shares at a price of $19.43 per share. This got rid of 1.51 million shares from the insider’s fortune and the stock experienced a 5.82 percent rally in price since the news became public. This exchange saw 1.24 million shares get out from the Executive Vice President & CFO account. On 08/19/2019, Executive Vice President & COO McLean Emmett E recorded a sale transaction valued at $1.84 million. The sale at $18.37 a share has eliminated 100 thousand shares from the insider’s portfolio position. Meanwhile, shares price witnessed 11.92 percent increase since the transaction reporting date. The company insider is left with 1.07 million shares remaining in the account. DAWSON G STEVEN, who works as Director at the company, performed a sale of 7.48 thousand shares in a transaction worth $135.09 thousand. The disposal recorded on 08/08/2019 was priced at $18.07 per share. The stock price soared 13.78 percent since the transaction. DAWSON G STEVEN currently holds a stake of 89.44 thousand in MPW stock which is worth $1.88 million after the insider selling.
On December 03, 2019, Medical Properties Trust, Inc. (NYSE:MPW) shares gained 2.24% or 0.46 points to close at $21.02 with a thin trading volume of 4.366 million shares. It opened the trading session at $20.53, the shares rose to $21.09 and dropped to $20.53, the range by which the price of stock traded the whole day. The company now has a market cap of $10.9 billion and currently has 518.94 million outstanding shares. Medical Properties Trust, Inc. (MPW) stock has accumulated 0.96 percent of market value in 21 trading days.
Stock analysts at BofA/Merrill, assumed coverage of shares of Medical Properties Trust, Inc. (NYSE:MPW) with Neutral recommendation, according to their opinion released on October 14. Analysts at KeyBanc Capital Markets issued an upgrade for the stock to Overweight from previous rating of Sector Weight, in a research note that dated back to August 07.
MPW stock’s trailing 3-year beta is 0.54, meaning there will be a lower rate of return, although posing a lower risk. The part of a firm’s profit given to each outstanding share of regular stock was $0.81 share in the trailing 52 weeks. The stock’s value surged 30.72 percent year to date (YTD) compared to a rise of 21.71 percent in 52 week’s period. The firm’s shares are still trading -0.14 percent below its 1-year high of $21.05 and 37.84 percent up from 52-week low of $15.25. The average consensus ranking on the company is 2.1, on a ranging where 5 is equal to a consensus sell rating. In other words, the mean analyst recommendations are ranking this stock as a sell.
Medical Properties Trust, Inc. (MPW) shares are trading at a P/E ratio of 26.3 times earnings posted in the trailing 12 months. The industry MPW deals with has an average P/E of 35.4. Its P/B ratio is standing at 1.8X compared to the 2.2 industry average. It is additionally sporting a 10.7 on the Price-to-Sales ratio, compared to the industry’s P/S average of 6.6. Medical Properties Trust, Inc. has a 98.3% gross profit margin, with its operating margin around 61.8%. Alongside this, the company’s net profit margin currently stands at 41%.
Past records have indicated that shares in Medical Properties Trust, Inc. declined on 21 different earnings reaction days and we have yet to see whether this trend will play out and remain in place when the company reports upcoming earnings. Investors will get the next hint of MPW’s Q4 earnings on February 04. Analysts are predicting revenue to climb 47.3 percent to $266M in the financial fourth quarter, while EPS will soar by about 14.29 percent to $0.24 per share. In the last quarter, it earnings of $0.31 per share came worse than the $0.32091, adjusted, expected by Thomson Reuters consensus estimate. Revenue for the quarter was $180.58M, topping the $179.68M analysts had expected. Earnings are seen to rise by 236.1 percent this year, 25.71 percent in the coming year.